Muismonoklonale antilichamen tegen Nivolumab (Clone: 8G6G3D8)

Nivolumab (Opdivo) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Nivolumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells. Anti-Nivolumab Antibody (8G6G3D8), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Nivolumab.

Nivolumab

8G6G3D8

ELISA

Protein A chromatography

Purified

0.5 mg/mL, lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.

The antibody is stable in lyophilized form if stored at -20°C or below. The reconstituted antibody can be stored for 2-3 weeks at 2-8°C. For long term storage, aliquot and store at -20°C or below. Avoid repeated freezing and thawing cycles.

ELISA detection: 0.01-0.1 μg/mL

Mouse IgG1